Vaccines against SARS-CoV-2 continue to be developed at an astonishingly quick speed and the early ones, like Pfizer and Moderna, have been shown to be more effective than many public health scientists had dared to hope. As COVID-19 vaccine research continues to progress, the world's eyes are turning toward medicine regulators. COVID-19 vaccines need to be authorized for use in each country in which the pharmaceutical industry intends to commercialize its product. This results in a patchwork of regulations that can influence the speed at which products are launched and the standards that govern them. In this research forum article, we discuss several key questions about COVID-19 vaccine regulations that should shape research on the next stage of the pandemic response. We call for a research agenda that looks into the political economy of pharmaceutical regulation, particularly from a comparative perspective, including Global South countries.

中文翻译：

---

COVID-19疫苗监管的政治经济学研究视角


针对 SARS-CoV-2 的疫苗继续以惊人的速度开发出来，辉瑞和 Moderna 等早期疫苗已被证明比许多公共卫生科学家敢于希望的更有效。随着 COVID-19 疫苗研究的不断进展，全世界的目光都转向了药品监管机构。 COVID-19 疫苗需要在制药行业打算将其产品商业化的每个国家/地区获得使用授权。这导致了监管的混乱，这些监管可能会影响产品的推出速度以及管理这些产品的标准。在这篇研究论坛文章中，我们讨论了有关 COVID-19 疫苗法规的几个关键问题，这些问题应该影响大流行应对下一阶段的研究。我们呼吁制定一项研究议程，特别是从比较的角度，包括全球南方国家，对药品监管的政治经济学进行研究。